{"analyses":[{"ciLowerLimit":"0.84","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.21","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.9561","paramType":"Hazard Ratio (HR)","paramValue":"1.01","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.5","upperLimit":"13.4","value":"11.3"},{"groupId":"OG001","lowerLimit":"10.1","upperLimit":"13.1","value":"11.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"315"},{"groupId":"OG001","value":"318"}],"units":"Participants"}],"description":"OS is defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive. OS was estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Necitumumab + Pemetrexed + Cisplatin\n\nNecitumumab: 800 mg (absolute dose) on Days 1 and 8 of every 3-week cycle, administered as an I.V. infusion\n\nPemetrexed: 500 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles\n\nCisplatin: 75 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles","id":"OG000","title":"Necitumumab + Pemetrexed + Cisplatin"},{"description":"Pemetrexed + Cisplatin\n\nPemetrexed: 500 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles\n\nCisplatin: 75 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles","id":"OG001","title":"Pemetrexed + Cisplatin"}],"paramType":"MEDIAN","populationDescription":"All randomized participants. Censored participants: Necitumumab + Pemetrexed + Cisplatin =79, Pemetrexed + Cisplatin=72","reportingStatus":"POSTED","timeFrame":"Randomization to Death from Any Cause (Up to 31.6 Months)","title":"Overall Survival Time (OS)","type":"PRIMARY","unitOfMeasure":"Months"}